Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28655810 | 0.80 | CA12 (0.55) | CA12CA9MEN1KMT2ANPC1 | |
| SCHEMBL28650967 | 0.76 | CA12 (0.50) | CA12CA9MEN1KMT2ANPC1 | |
| SCHEMBL3170290 | 0.74 | ALDH1A1 (0.52) | CA12CA9MEN1KMT2ACHRM2 | |
| SCHEMBL13484325 | 0.74 | ALDH1A1 (0.52) | CA12CA9MEN1KMT2ACHRM2 | |
| SCHEMBL5962347 | 0.74 | CHRM2 (0.54) | CA12CA9MEN1KMT2ACHRM2 | |
| SCHEMBL9625482 | 0.74 | CHRM2 (0.63) | MEN1KMT2ACHRM2ALDH1A1 | |
| SCHEMBL31385569 | 0.73 | CA12 (0.55) | CA12CA9MEN1KMT2ANPC1 | |
| SCHEMBL291933 | 0.73 | CA12 (0.55) | CA12CA9MEN1KMT2ANPC1 | |
| SCHEMBL7286379 | 0.72 | CHRM2 (0.53) | CA12CA9MEN1KMT2ACHRM2 | |
| SCHEMBL14908703 | 0.72 | CA12 (0.42) | CA12CA9MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844366-B2 | Sulfonamide hydroxamates | SYNTEX (U.S.A.) LLC (US) | 2005-01-18 | — | — | US | disclosed |
| US-6787559-B2 | HYDROXYCARBONYL OR ALKYLOXYCARBONYL OR AMINOHYDROXYCARBONYL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PROCOLLAGEN C-PROTENASE INHIBITOR | SYNTEX (U.S.A.) LLC. | 2004-09-07 | — | — | US | disclosed |
| EP-1149072-B1 | SULFONAMIDE HYDROXAMATES | HOFFMANN LA ROCHE (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | BILLLEDEAU ROLAND JOSEPH (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030199520-A1 | Sulfonamide hydroxamates | BILLLEDEAU ROLAND JOSEPH (US) | 2003-10-23 | — | — | US | disclosed |
| US-6492394-B1 | PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES | SYNTEX (U.S.A.) LLC | 2002-12-10 | — | — | US | disclosed |
| EP-1149072-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000037436-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | CTSE, PREP, HPN | CA12 1416/4885CA9 581/4885MEN1 3614/4885 |
| US-20030199520-A1 | Sulfonamide hydroxamates | MMP3, TIMP3, MMP13 | CA12 126/4885CA9 122/4885MEN1 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.